A large European study found that only 60% of patients with heart failure were treated according to the ESC guidelines for the five most commonly used cardiac drugs. Adherence to treatment guidelines was independently correlated with patient outcomes, including hospitalization rates and time to readmission.
A recent study found that only three out of 21 streptokinase preparations met the minimum requirements of the European Pharmacopoeia, highlighting the need for stricter calibration and monitoring. The lack of reliable testing methods and inadequate post-marketing control allow substandard drugs to enter the market.
The new guidelines emphasize the importance of timely thrombolysis and PCI, with a focus on reducing delays in treatment. They also highlight the benefits of primary PCI over thrombolysis in certain situations.
The European Society of Cardiology has launched a new initiative called Women at Heart to improve the handling of women with cardiovascular disease. The initiative aims to highlight the growing burden and under-appreciation of women's heart disease, and promote better understanding and treatment among medical professionals.
A European Society of Cardiology consensus report recommends regular physical examination, detailed medical history investigation, and a 12-lead ECG for all young athletes involved in organized sport. This could potentially cut sports-related cardiac deaths by 50%-70% if implemented across Europe.
Bone marrow derived stem cells can give rise to heart muscle cells through transdifferentiation, a process that has sparked debate and potential applications in heart repair and transplantation. The concept challenges traditional dogma of tissue specific stem cell differentiation in adults.
A new study found that eccentric muscle training, such as hiking downhill, improves glucose tolerance by 25.0%, compared to 9.4% with concentric training, like hiking uphill. This research provides insight into the specific metabolic effects of different types of exercise on glucose metabolism in humans.
The Euro Heart Survey on diabetes and the heart found abnormal glucose regulation is common in patients with coronary artery disease. Patients with diabetes face a dismal prognosis, but those without known diabetes can benefit from improved treatment standards.
Women with diabetes having acute coronary syndrome are at a higher risk of presenting with ST-elevation-ACS and dying in hospital, compared to men. Diabetes has a differential effect on the pathophysiology of ACS based on patient sex.
Researchers found that embryonic endothelial progenitor cells could reduce infarct size and improve regional myocardial function when delivered regionally, but not systemically. This study uses a large animal model to test the cardioprotective potential of these cells, paving the way for future human trials.
The study found that approximately 1 in 5 subjects had previously undiagnosed diabetes, while over 1 in 4 had impaired glucose tolerance. Lifestyle changes and medication may help prevent the progression of impaired glucose tolerance to full-blown diabetes and its associated complications.
Following guidelines improved acute reperfusion and adjunctive treatment of STEMI in diabetics, leading to a 36% relative reduction in hospital mortality. Diabetes mellitus significantly increases the risk of developing coronary artery disease.
The Azithromycin and Coronary Events Study (ACES) found no reduction in cardiovascular events among participants treated with azithromycin. The study suggests that Chlamydia pneumoniae may not play a significant role in the late-stage development of coronary heart disease.
The landmark PROVE IT-TIMI 22 trial found that a long-term regimen of antibiotics designed to kill Chlamydia pneumoniae does not reduce the risk of heart attacks or cardiovascular disease. Researchers recommend focusing on proven therapies like high-dose statin therapy and ACE inhibitors instead.
The trial found that early and aggressive statin use can reduce the long-term incidence of heart attacks, death from heart attack, stroke or readmission to the hospital for a cardiac event. However, benefits only became evident longer term, with no differences in endpoints during the first four months.
The European Society of Cardiology provides recommendations for athletes with cardiovascular disease, balancing risks and benefits of competitive sport. The panel aims to inform physicians and cardiologists about safe sport activities for candidates with cardiovascular abnormalities.
The study group report emphasizes the need for systematic screening by 12-lead ECG to identify hypertrophic cardiomyopathy and other lethal cardiovascular diseases. The consensus document advocates for a common European screening protocol based on 12-lead ECG to prevent sports-related sudden death.
The ADONIS trial found that dronedarone significantly decreased the risk of a first recurrence of atrial fibrillation or flutter within the 12-month study period by 27.5% compared to placebo. The drug also displayed good cardiac tolerability with no cases of torsades de pointes.
A worldwide survey of catheter ablation for atrial fibrillation found varying methods, effectiveness, and complications. The study reported a significant increase in procedures, but also noted major complications such as early deaths, strokes, and tamponade.
The EURIDIS trial demonstrated that dronedarone significantly lowers the risk of first recurrence of AF/AFL within the 12-month study period by 21.6% compared to placebo. Dronedarone proved effective for all recurrences of atrial fibrillation or flutter, including those that were symptomatic.
Rimonabant has been shown to improve body weight, waist circumference, lipid profiles, and glycemic control. Patients taking rimonabant 20mg/day lost an average of 8.6kg, while those on placebo gained 4.8kg.
The final pooled analysis of SPORTIF III and V1,2 confirms ximelagatran's effectiveness in preventing strokes in patients with atrial fibrillation. Ximelagatran offers a safer alternative to warfarin without coagulation monitoring or dose titration, reducing the risk of stroke by 62%.
The ACTION study found that adding nifedipine to existing treatments for stable angina reduces the need for hospital interventions by 13% and prevents heart attacks and strokes. Nifedipine also reduces hospitalizations for heart failure in patients with stable angina.
The ICTUS study found that early invasive and selective invasive strategies are equivalent treatment options for patients with nSTE-ACS and elevated cardiac troponin. The study showed higher myocardial infarction rates but fewer rehospitalizations in the early invasive group.
Patients with atrial fibrillation are at increased risk for stroke and clotting complications, yet a significant percentage do not receive recommended clot-preventing medications. Asymptomatic patients should instead receive simple rate controlling drugs like beta-blockers, digitalis or verapamil.
The European Society of Cardiology awarded Ireland's Minister for Health and Children the Gold Medal for his efforts to move cardiovascular disease up the political agenda. The Minister has led initiatives in public health and medical arenas, including heart health promotion and data registration standards.
The European Society of Cardiology is calling for consistency across Europe in terms of data collection and analysis in cardiology. The CARDS meeting aims to agree European data standards, enabling local, national and international comparisons of data using set standards.